|Day Low/High||158.06 / 162.50|
|52 Wk Low/High||90.14 / 196.00|
Jim Cramer says the market can have many winners.
Legalization of marijuana for medical reasons or otherwise is already on the ballot in Arkansas, California, North Dakota and several other states.
Marijuana is on the ballot in several states this election cycle, and its approval could be a boon for those in the business -- though obstacles remain.
Shares of these cannabis companies are ready for huge growth if November is a successful month for legalization.
The company's share price has increased 1,500% since 2013.
But the buyers are still unable to produce sustained momentum.
Analysts are predicting that the legal pot market could reach $6.7 billion in sales this year.
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
GW Pharma could be the answer to an opiate addiction that isn't understood.
Cramer continues to back Apple and says Align Technology is a stock to buy now.
Investors hate uncertainty, Cramer says, but uncertainty creates bargains.
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
GW Pharmaceuticals (GWPH) said on Monday its seizure drug epidiolex had positive results in a late-stage clinical trial.
Cramer is sticking with International Paper and likes Advanced Micro Devices.
This is not the time to sell in a panic, Cramer says.
The marijuana market is heating up as marijuana usage for medical and recreational purposes gains legitimacy.
GW Pharmaceuticals (GWPH) reportedly hired Morgan Stanley after it was approached by several companies about a possible takeover.
Cramer says sell Stryker and buy Zimmer Biomet, and take Randgold over Barrick Gold.
The economy needs consumers to buy, buy, buy but so far consumers have been all over the map, Cramer says.
Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.
Investors should stick with buying stocks in the utilities and consumer staples sectors, which rose higher in the aftermath of the Brexit vote and avoided the massive volatility.
Shares of GW Pharmaceuticals are on the rise after the company announced this morning positive Phase 3 results for its Epidiolex for the treatment of Lennox-Gastaut syndrome, or LGS.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.